Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties
作者:Janet Gunzner-Toste、Guiling Zhao、Paul Bauer、Timm Baumeister、Alexandre J. Buckmelter、Maureen Caligiuri、Karl H. Clodfelter、Bang Fu、Bingsong Han、Yen-Ching Ho、Nikolai Kley、Xiaorong Liang、Bianca M. Liederer、Jian Lin、Sophie Mukadam、Thomas O’Brien、Angela Oh、Dominic J. Reynolds、Geeta Sharma、Nicholas Skelton、Chase C. Smith、Jasleen Sodhi、Weiru Wang、Zhongguo Wang、Yang Xiao、Po-wai Yuen、Mark Zak、Lei Zhang、Xiaozhang Zheng、Kenneth W. Bair、Peter S. Dragovich
DOI:10.1016/j.bmcl.2013.04.040
日期:2013.6
Potent, reversible inhibition of the cytochrome P450 CYP2C9 isoform was observed in a series of urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors. This unwanted property was successfully removed from the described inhibitors through a combination of structure-based design and medicinal chemistry activities. An optimized compound which did not inhibit CYP2C9 exhibited potent
在一系列含脲的烟酰胺磷酸核糖基转移酶(NAMPT)抑制剂中观察到对细胞色素P450 CYP2C9同工型的有效可逆抑制作用。通过基于结构的设计和药物化学活性的结合,已成功地从所述抑制剂中去除了这种不需要的特性。一种不抑制CYP2C9的优化化合物具有有效的抗NAMPT活性(17 ; BC NAMPT IC 50 = 3 nM; A2780抗增殖IC 50 = 70 nM),小鼠PK性能良好,在A2780小鼠异种移植模型中有效。还描述了该化合物与NAMPT蛋白复合的晶体结构。